Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 584

1.

Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease.

Manaud G, Nossent EJ, Lambert M, Ghigna MR, Boët A, Vinhas MC, Ranchoux B, Dumas SJ, Courboulin A, Girerd B, Soubrier F, Bignard J, Claude O, Lecerf F, Hautefort A, Florio M, Sun B, Nadaud S, Verleden SE, Remy S, Anegon I, Bogaard HJ, Mercier O, Fadel E, Simonneau G, Vonk Noordegraaf A, Grünberg K, Humbert M, Montani D, Dorfmüller P, Antigny F, Perros F.

Am J Respir Cell Mol Biol. 2020 Mar 25. doi: 10.1165/rcmb.2019-0015OC. [Epub ahead of print]

PMID:
32209028
2.

Portopulmonary hypertension in the current era of pulmonary hypertension management.

Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O.

J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119-7. doi: 10.1016/j.jhep.2020.02.021. [Epub ahead of print]

PMID:
32145258
3.

Phenotype and outcome of PAH patients carrying a TBX4 mutation.

Thoré P, Girerd B, Jaïs X, Savale L, Ghigna MR, Eyries M, Levy M, Ovaert C, Servettaz A, Guillaumot A, Dauphin C, Chabanne C, Boiffard E, Cottin V, Perros F, Simonneau G, Sitbon O, Soubrier F, Bonnet D, Remy-Jardin M, Chaouat A, Humbert M, Montani D.

Eur Respir J. 2020 Feb 20. pii: 1902340. doi: 10.1183/13993003.02340-2019. [Epub ahead of print]

PMID:
32079640
4.

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.

Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM.

J Heart Lung Transplant. 2020 Apr;39(4):300-309. doi: 10.1016/j.healun.2019.12.013. Epub 2020 Jan 21.

5.

The revised definition of pulmonary hypertension: exploring the impact on patient management.

Simonneau G, Hoeper MM.

Eur Heart J Suppl. 2019 Dec;21(Suppl K):K4-K8. doi: 10.1093/eurheartj/suz211. Epub 2019 Dec 17.

6.

Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France.

Hachulla E, Launay D, Boucly A, Mouthon L, de Groote P, Cottin V, Pugnet G, Prévôt G, Bourlier D, Dauphin C, Chaouat A, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O, Giovannelli J.

Chest. 2019 Nov 19. pii: S0012-3692(19)34216-3. doi: 10.1016/j.chest.2019.10.045. [Epub ahead of print]

7.

A roadmap for management of chronic thromboembolic pulmonary hypertension.

Jaïs X, Brenot P, Montani D, Fadel E, Humbert M, Simonneau G.

Eur Respir J. 2019 Oct 24;54(4). pii: 1901295. doi: 10.1183/13993003.01295-2019. Print 2019 Oct. No abstract available.

PMID:
31649145
8.

Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.

McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM; AMBITION Study Group.

J Heart Lung Transplant. 2019 Dec;38(12):1286-1295. doi: 10.1016/j.healun.2019.09.010. Epub 2019 Sep 17.

9.

Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension.

Seferian A, Jaïs X, Savale L, Jevnikar M, Ghigna MR, Weatherald J, Assoun S, Fadel E, Simonneau G, Sitbon O, Humbert M, Montani D.

Respir Med Res. 2019 Nov;76:48-53. doi: 10.1016/j.resmer.2019.06.002. Epub 2019 Jul 9.

PMID:
31557688
10.

Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.

Savale L, Habibi A, Lionnet F, Maitre B, Cottin V, Jais X, Chaouat A, Artaud-Macari E, Canuet M, Prevot G, Chantalat-Auger C, Montani D, Sitbon O, Galacteros F, Simonneau G, Parent F, Bartolucci P, Humbert M.

Eur Respir J. 2019 Dec 4;54(6). pii: 1900585. doi: 10.1183/13993003.00585-2019. Print 2019 Dec. Erratum in: Eur Respir J. 2020 Jan 30;55(1):.

PMID:
31537700
11.

Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry.

Barco S, Klok FA, Konstantinides SV, Dartevelle P, Fadel E, Jenkins D, Kim NH, Madani M, Matsubara H, Mayer E, Pepke-Zaba J, Simonneau G, Delcroix M, Lang IM.

J Thromb Haemost. 2020 Jan;18(1):151-161. doi: 10.1111/jth.14629. Epub 2019 Sep 24.

PMID:
31479557
12.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
13.

Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension.

Taniguchi Y, Jaïs X, Jevnikar M, Boucly A, Weatherald J, Brenot P, Planche O, Parent F, Savale L, Fadel E, Montani D, Humbert M, Sitbon O, Simonneau G.

J Heart Lung Transplant. 2019 Aug;38(8):833-842. doi: 10.1016/j.healun.2019.04.006. Epub 2019 Apr 27.

PMID:
31103383
14.

Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features.

Hoette S, Creuzé N, Rochitte CE, Simonneau G, Humbert M, Souza R, Chemla D.

Pulmonology. 2019 Jul - Aug;25(4):248-251. doi: 10.1016/j.pulmoe.2019.03.002. Epub 2019 May 10.

15.

French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Brenot P, Jaïs X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, Mercier O, Fabre D, Parent F, Jevnikar M, Montani D, Savale L, Sitbon O, Fadel E, Humbert M, Simonneau G.

Eur Respir J. 2019 May 18;53(5). pii: 1802095. doi: 10.1183/13993003.02095-2018. Print 2019 May.

16.

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF.

Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

17.

An insider view on the World Symposium on Pulmonary Hypertension.

Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Lancet Respir Med. 2019 Jun;7(6):484-485. doi: 10.1016/S2213-2600(19)30111-0. Epub 2019 Apr 4. No abstract available.

PMID:
30956061
18.

EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.

Benza R, Corris P, Ghofrani A, Kanwar MK, McLaughlin VV, Raina A, Simonneau G.

Pulm Circ. 2019 Feb 26:2045894019837849. doi: 10.1177/2045894019837849. [Epub ahead of print] No abstract available.

19.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

20.

An overview of the 6th World Symposium on Pulmonary Hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir J. 2019 Jan 24;53(1). pii: 1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. No abstract available.

21.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.

22.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

23.

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, Maître B, Huertas A, Jaïs X, Weatherald J, Montani D, Sitbon O, Simonneau G, Galactéros F, Humbert M, Bartolucci P, Savale L.

Eur Respir J. 2018 Oct 10;52(4). pii: 1800272. doi: 10.1183/13993003.00272-2018. Print 2018 Oct.

PMID:
30305330
24.

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.

Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, Dauphin C, Chaouat A, Savale L, Jaïs X, Jevnikar M, Traclet J, De Groote P, Simonneau G, Hachulla E, Mouthon L, Montani D, Humbert M, Sitbon O.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800678. doi: 10.1183/13993003.00678-2018. Print 2018 Oct.

PMID:
30209196
25.

Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery.

Amsallem M, Guihaire J, Arthur Ataam J, Lamrani L, Boulate D, Mussot S, Fabre D, Taniguchi Y, Haddad F, Sitbon O, Jais X, Humbert M, Simonneau G, Mercier O, Brenot P, Fadel E.

J Heart Lung Transplant. 2018 Sep;37(9):1102-1110. doi: 10.1016/j.healun.2018.05.004. Epub 2018 May 24.

PMID:
30037729
26.

Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension.

Chemla D, Weatherald J, Lau EMT, Savale L, Boucly A, Attal P, Jaïs X, Parent F, Girerd B, Simonneau G, Montani D, Humbert M, Sitbon O, Hervé P.

Chest. 2018 Oct;154(4):882-892. doi: 10.1016/j.chest.2018.06.015. Epub 2018 Jun 27.

PMID:
29940163
27.

Factors predicting outcome after pulmonary endarterectomy.

Tromeur C, Jaïs X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E.

PLoS One. 2018 Jun 21;13(6):e0198198. doi: 10.1371/journal.pone.0198198. eCollection 2018.

28.

Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, Jevnikar M, Savale L, Jaïs X, Peng M, Simonneau G, Montani D, Humbert M, Sitbon O.

Chest. 2018 Oct;154(4):872-881. doi: 10.1016/j.chest.2018.05.006. Epub 2018 May 22.

PMID:
29800550
29.

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.

Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, Sitbon O, Jaïs X, Savale L, Weatherald J, Sobanski V, Mathai SC, Shafiq M, Cordier JF, Hachulla E, Simonneau G, Humbert M.

PLoS One. 2018 May 15;13(5):e0197112. doi: 10.1371/journal.pone.0197112. eCollection 2018.

30.

Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Taniguchi Y, Brenot P, Jais X, Garcia C, Weatherald J, Planche O, Fadel E, Humbert M, Simonneau G.

Chest. 2018 Sep;154(3):521-531. doi: 10.1016/j.chest.2018.03.059. Epub 2018 May 3.

31.

Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations.

Montani D, Dorfmüller P, Girerd B, Le Pavec J, Fadel E, Simonneau G, Sitbon O, Humbert M.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):537-541. doi: 10.1164/rccm.201802-0317LE. No abstract available.

PMID:
29702008
32.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

33.

Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension.

Le Hiress M, Akagah B, Bernadat G, Tu L, Thuillet R, Huertas A, Phan C, Fadel E, Simonneau G, Humbert M, Jalce G, Guignabert C.

J Med Chem. 2018 Apr 12;61(7):2725-2736. doi: 10.1021/acs.jmedchem.7b01312. Epub 2018 Mar 19.

PMID:
29526099
34.

[Pulmonary veno-occlusive disease].

Boucly A, Girerd B, Bourlier D, Nemlaghi S, Caliez J, Savale L, Jaïs X, Dorfmüller P, Simonneau G, Sitbon O, Humbert M, Montani D.

Rev Mal Respir. 2018 Feb;35(2):160-170. doi: 10.1016/j.rmr.2017.11.005. Epub 2018 Mar 1. Review. French.

PMID:
29501213
35.

Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Montani D, Henry J, O'Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y.

Respiration. 2018;95(4):244-250. doi: 10.1159/000485631. Epub 2018 Feb 28.

36.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

37.

RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Hoette S, Creuzé N, Günther S, Montani D, Savale L, Jaïs X, Parent F, Sitbon O, Rochitte CE, Simonneau G, Humbert M, Souza R, Chemla D.

Lung. 2018 Apr;196(2):157-164. doi: 10.1007/s00408-018-0089-7. Epub 2018 Feb 12.

PMID:
29435740
38.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

39.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

40.

Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?

Simonneau G, Humbert M.

Am J Respir Crit Care Med. 2018 May 15;197(10):1364-1365. doi: 10.1164/rccm.201712-2483LE. No abstract available.

PMID:
29272591
41.

The changing landscape of chronic thromboembolic pulmonary hypertension management.

Madani M, Ogo T, Simonneau G.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170105. doi: 10.1183/16000617.0105-2017. Print 2017 Dec 31. Review.

42.

Acute decompensated pulmonary hypertension.

Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, Jevnikar M, Montani D, Mercier O, Simonneau G, Fadel E, Sitbon O, Humbert M.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170092. doi: 10.1183/16000617.0092-2017. Print 2017 Dec 31. Review.

43.

Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.

Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M, Thomas de Montpréville V, Girerd B, Jaïs X, Savale L, Mercier O, Fadel E, Soubrier F, Sitbon O, Simonneau G, Vonk Noordegraaf A, Humbert M, Perros F, Dorfmüller P.

J Heart Lung Transplant. 2018 May;37(5):647-655. doi: 10.1016/j.healun.2017.09.022. Epub 2017 Oct 4.

PMID:
29108819
44.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
45.

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jaïs X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Hervé P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O.

Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.

PMID:
29070502
46.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L.

Eur Respir J. 2017 Oct 19;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.

47.

Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story.

Simonneau G, Humbert M.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):704-706. doi: 10.1164/rccm.201709-1962ED. No abstract available.

PMID:
29043836
48.

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators.

Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11.

PMID:
28919201
49.

Are indexed values better for defining exercise pulmonary hypertension?

Weatherald J, Boucly A, Lau E, Godinas L, Savale L, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Chemla D, Hervé P.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700240. doi: 10.1183/13993003.00240-2017. Print 2017 Sep. No abstract available.

50.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

Supplemental Content

Loading ...
Support Center